Our previous work has shown that, in the normal circulation, insulin-like growth factor-binding protein-1 (IGFBP-1) is present as a single highly phosphorylated species. In this study, we have purified this previously uncharacterized isoform of IGFBP-1 to determine its ligand-binding affinity and the potential significance of highly phosphorylated IGFBP-1. Immunoaffinity chromatography was used to isolate IGFBP-1 from normal human plasma and from human hepatoma (Hep G2) cell medium as an alternative source of the IGFBP-1 phosphoform in the circulation. The affinity of this highly phosphorylated IGFBP-1 was compared with that of nonphosphorylated IG-FBP-1 and recombinant human (rh) IGFBP-3 by equilibrium binding to IGF-I and IGF-II.
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) also was significantly higher than the affinity of IGFBP-3 for IGF-I (5.6 Ϯ 4.2 ϫ 10 9 M Ϫ1 , P Ͻ 0.005). These data suggest that the highly phosphorylated IGFBP-1 in the normal circulation will preferentially bind IGF-I rather than IGF-II, whereas in pregnancy, the affinity of IGFBP-1 for IGF-I will be reduced because of the appearance of non-and lesser-phosphorylated forms. This lends support to the theory that changes in IGFBP-1 phosphorylation may influence the modulatory effects of IGFBP-1 on IGF bioavailability. (Endocrinology 138: 1130 -1136, 1997) T HE INSULIN-LIKE growth factors (IGF-I and -II) are present in extracellular fluids bound to specific, high affinity, binding proteins (IGFBPs) that modulate their activity at the cellular level (1, 2) . One of these binding proteins, IGFBP-1, has been shown to both inhibit and potentiate the actions of IGF-I (3) (4) (5) . These seemingly discrepant findings may be explained by the existence of several IGFBP-1 isoforms (5) . Phosphorylated IGFBP-1 variants, as well as the unmodified peptide, have been identified in amniotic fluid (AF) (6) , a commonly used source of IGFBP-1, and in other biological fluids and tissues (7, 8) . These variants have been found to augment the effects of IGF-I on porcine smooth muscle cells (4, 6) , whereas more highly phosphorylated isoforms, isolated from human hepatoma (Hep G2) cell conditioned medium (CM), did not (6) . In vivo studies of wound healing, performed both in rats (9, 10) and humans (11) , reflect in vitro findings; nonphosphorylated IGFBP-1 enhances IGF-I-stimulated wound repair, whereas phosphorylated IGFBP-1 is inhibitory of IGF trophic actions.
We have shown that in the normal adult human circulation, IGFBP-1 is present as a single, highly phosphorylated species; this phosphoform is not found in AF (12) . However, circulating IGFBP-1 phosphorylation status can be altered, and this is particularly evident during pregnancy, when nonand lesser-phosphorylated variants increase markedly in the maternal circulation (12) . Phosphorylation of IGFBP-1 has been reported to increase affinity for ligand (6) ; thus, changes in the phosphorylation status of IGFBP-1 may influence the ability of IGF to interact with its cell surface receptors.
In adult human serum, IGFBP-3 is thought to be saturated with IGF-I or -II, forming the 150 kDa complex with the acid-labile glycoprotein (13, 14) . In contrast, the low-molecular mass-binding proteins, which form the 40 -50 kDa complex, are thought to be unsaturated. Evidence for this comes from cross-linking of iodinated IGF-I to serum, which demonstrates binding to these species but not to IGFBP-3 (15) . In addition, gel filtration chromatography of serum from humans injected with radiolabeled IGF-I shows that the labeled IGF-I is initially present in the 40 -50 kDa complex (16) . This has led some investigators to question the functional importance of IGFBP-1 in terms of regulating IGF bioavailability and actions.
The aim of this study was to determine the significance of changes to IGFBP-1 phosphorylation status by comparing the ligand-binding affinities of the normal circulating phosphoform with those of nonphosphorylated IGFBP-1. Because circulating IGFBP-1 is mainly derived from the liver, we investigated the possibility of using a liver cell line (Hep G2 cells) as a source of the phosphorylated isoform of IGFBP-1 found in plasma. In addition, the affinity of the previously uncharacterized plasma phosphoform of IGFBP-1 was compared with that of IGFBP-3, the main IGF carrier in the circulation.
Materials and Methods
Sources of IGFBP-1
IGFBP-1 was purified from two sources: plasma and the CM of a human hepatocyte carcinoma cell line (Hep G2). Plasma was obtained from healthy female volunteers who were taking a combined oral contraceptive pill; we have shown previously that circulating IGFBP-1 is elevated in such subjects, but the phosphorylation status of the IGFBP-1 is unchanged, because only the single, highly phosphorylated isoform is present (17) . The origin of circulating IGFBP-1 is the liver, and therefore, the Hep G2 cells were investigated as a potential source of the circulating phosphoform.
Culture of Hep G2 cells
Hep G2 cells (85011430, passage number 90) obtained from the European Collection of Animal Cell Cultures (Porton Down, Salisbury, UK) were cultured in DMEM supplemented with 10% FCS, 1% nonessential amino acids, 0.04 mm L-glutamine, and 1 mm pyruvate. Biochemical analysis and RIA (see below) of the growth medium indicated that bovine IGFBP-1 does not cross-react with the antibodies used in this study. The cells were grown in 5% carbon dioxide at 37 C until confluent, at which point the medium was harvested and the cells passaged 1:4 after trypsinization.
Immunoaffinity chromatography
Immunoaffinity chromatography was used to isolate IGFBP-1 from normal plasma (NP) or Hep G2-CM. Monoclonal antibody (MAb) 6303 (a generous gift of Medix Biochemica, Kauniainen, Finland), which recognizes all IGFBP-1 variants (12), was coupled to Sephacryl S-300 (11) at 1 mg/ml to form the immunoaffinity matrix. A 10-ml column was equilibrated for 24 h at 4 C by the application of PBS/0.25% BSA/0.1% Tween 20 at a flow rate of 5 ml/h. Next, 250 ml plasma or 500 ml Hep G2 CM was recirculated through the column for 72 h at a flow rate of 3.75 ml/h, the column was washed with 100 ml Tris buffer, pH 8.0 (50 mm Tris/0.5 m NaCl/0.1% Tween 20) , and the bound peptide was eluted by application of 0.1 m hydrochloric acid. Then, 10 ϫ 1-ml fractions were collected into tubes containing 200 l 1 m Tris pH 9.0 and analyzed for IGFBP-1 by RIA (see below). Fractions containing more than 100 g/l IGFBP-1 were pooled and concentrated by centrifugation through Centricon 10 filters (Amicon, Stonehouse, Gloucestershire, UK). The particular IGFBP-1 isoforms contained within the concentrate were assessed by n-octyl glucoside (n-OG) electrophoresis and Western ligand blotting with 125 I-IGF-I (see below).
HPLC
One hundred microliters of concentrate obtained from the 6303 immunoaffinity column or 1 g rhIGFBP-1 (kindly donated by Amgen, Boulder, Co) dissolved in 0.02 m Tris/0.1 m NaCl/2% isopropanol, (pH 9.5) were applied to a 4.6 ϫ 150 mm Hema Mono Q column (Alltech, Camforth, UK). Sample was eluted isocratically for 5 min with 0.02 m Tris/0.1 m NaCl/20% isopropanol followed by a linear gradient to 0.02 m Tris/0.3 m NaCl/20% isopropanol over 20 min. The flow rate was 1.5 ml/min, and absorbance was monitored at 220 nm. Then, 50 ϫ 30s fractions were collected and analyzed for IGFBP-1 by RIA and n-OG electrophoresis/Western ligand blot (see below).
IGFBP-1 RIA
IGFBP-1 levels in the fractions from the immunoaffinity and IEX columns were determined using our previously reported RIAs, RIA 6303 and RIA 6305 (12) . The assays use rhIGFBP-1 (a kind gift of Dr. L. Fryklund, Pharmacia, Stockholm, Sweden), for standards (1-250 g/l) and radiolabel, and either MAb 6303 or 6305 (generously provided by Medix Biochemica, Kauniainen, Finland). RIA 6303 recognizes all isoforms of IGFBP-1, including the phosphoform characteristic of NP, whereas MAb 6305 does not recognize the circulating phosphoform, and therefore, the 6305 RIA only detects the non-and lesser-phosphorylated isoforms (12) .
Biochemical characterization of IGFBP-1 isoforms
The IGFBP-1 isoforms in the NP, Hep G2 CM, and the fractions from the immunoaffinity and IEX columns were characterized by immunoprecipitation, n-OG electrophoresis, and Western ligand blotting, as previously described (6, 12) . Samples were incubated at 4 C overnight with 250 l MAb 6303 or 6305 (1:1000 dilution). Precipitating antibody (250 l antimouse coated cellulose suspension (Sac-Cel; IDS, Tyne and Wear, Boldon, UK) was then added and incubated for 1 h at 37 C. Bound antibody was separated by centrifugation at 1000 ϫ g for 10 min. The precipitated proteins were washed (ϫ3) by the addition of 1 ml PBS/ 0.25% BSA/0.1% tween 20 and centrifuged at 1000 ϫ g for 10 min before resuspending in 100 l gel loading buffer [170 mm Tris.HPO 4 pH 5.5/90 mm n-OG (Sigma, Poole, Dorset, UK)/40% glycerol/0.008% bromophenol blue]. All samples were boiled for 5 min before loading onto a stacking gel of 4% acrylamide, which, like the resolving gel (15% acrylamide), contained the nonionic detergent n-OG at 20 mm. The gels were run at a constant voltage of 175V for approximately 6 h. After transfer onto nitrocellulose membranes, the proteins were incubated with 150,000 cpm/ml 125 I-IGF-I for 4 h at 25 C, washed, and visualized by autoradiography (5 days exposure).
Treatment of purified plasma and Hep G2 phosphoform with alkaline phosphatase
The highly phosphorylated IGFBP-1 isoform, obtained from IEX HPLC of plasma and Hep G2 CM, was incubated with 1 U calf intestinal alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN) for 2 h at 37 C. Samples were then subjected to immunoprecipitation and Western ligand blotting, as described above.
Assay of IGFBP binding to IGFs
Ligand-binding assays were performed with 125 I IGF-I or -II in the presence of unlabeled IGF-I or IGF-II to determine the relative affinities of rhIGFBP-1, the highly phosphorylated IGFBP-1 isoform, purified from plasma and Hep G2 CM and rhIGFBP-3 (recombinant IGFBP-3 was used in these studies because Sommer et al. (18) and Mukku et al. (19) have shown that posttranslational modifications do not affect its affinity for ligand.). The concentration yielding 25% specific binding was first determined for each IGFBP preparation from dilution curves established with 125 I IGF-I or -II. 125 I-labeled rhIGF-I (18, 500 cpm; specific activity 185 Ci/g) or 125 I-rhIGF-II (25,000 cpm; specific activity 255 Ci/g) was incubated with 10 g/liter IGFBP-1or 1 g/liter IGFBP-3 in the presence of unlabeled IGF-I or -II (final concentration 0 -40 ng/ml). The reactions were performed in triplicate overnight at 4 C in 0.25 ml 0.1 m HEPES/44 mm NaH 2 PO 4 /0.01% Triton X-100/0.25% BSA/0.02% sodium azide, pH 6.0). Bound label was separated from free by adding 250 l 1% human ␥-globulin and 500 l 25% polyethylene glycol (M r 8000; Sigma) and centrifugation at 1000 ϫ g for 15 min. The pellet was washed with 1 ml 6.25% polyethylene glycol and the final pellet counted in a ␥ spectrometer. Nonspecific binding was determined by measuring the amount of 125 I-IGF-I/-II that could be precipitated in the presence of 1.0 g/l unlabeled IGF.
To confirm the effect of phosphorylation on the affinity of IGFBP-1 for IGF, the dephosphorylated plasma phosphoform was subjected to ligand-binding assays, as described above.
Statistical analysis
The Simfit program (20) , kindly provided by Dr. W. G. Bardsley, University of Manchester, Manchester, UK, was used to analyze the ligand-binding data, and the Mann-Whitney U test for nonparametric data was used to compare the mean affinities of the various IGFBP preparations for their ligands.
Results
Characterization of IGFBP-1 isoforms in Hep G2-CM
Because the highly phosphorylated circulating form of IGFBP-1 is of hepatic origin, human hepatoma (Hep G2) cells were investigated as a potential source of the NP phosphoform. CM from HepG2 cells (HepG2 CM) was immunoprecipitated with either MAb 6303 or 6305 and then analyzed by n-OG electrophoresis and Western ligand blotting (Fig. 1) . Only MAb 6303 recognizes all IGFBP-1 variants. MAb 6305 does not detect the isoform found in the circulation (lane 4), and this highly phosphorylated form of IGFBP-1 was not present in AF (lane 2). Hep G2 cells do produce the IGFBP-1 phosphoform found in the normal circulation; however, multiple lesser-phosphorylated isoforms and nonphosphorylated IGFBP-1 also were present (lane 5).
Purification of IGFBP-1 isoforms
Immunoaffinity chromatography was used to isolate IGFBP-1 from Hep G2 CM; separation of the different phosphoforms then was achieved by IEX HPLC. The resulting chromatogram is shown in Fig. 2A . The upper line represents the elution profile and the lower line, a fitted baseline used for calculation of peaks. A species (peak a) with identical retention time to rh (nonphosphorylated) IGFBP-1 (Fig. 2B) was apparent, and in addition, the IGFBP-1 prepared from Hep G2 CM separated into several other discrete peaks (peaks b-e) with increased retention times, suggesting the separation of variantly phosphorylated isoforms.
The fractions collected from IEX chromatography of both rhIGFBP-1 and IGFBP-1 purified from HepG2 CM were analyzed by RIA 6303 and RIA 6305, and the results are shown in Fig. 3 . All fractions corresponding to chromatographic peaks contained IGFBP-1. With rhIGFBP-1, both assays measured approximately the same level of IGFBP-1 in each of the fractions (Fig. 3A) ; however, this was not true for the fractions obtained from IEX-chromatographic analysis of IGFBP-1 purified from HepG2 CM. Unlike RIA 6303, RIA 6305 failed to detect any IGFBP-1 in the fraction corresponding to the peak e, suggesting that this fraction contained the circulating IGFBP-1 phosphoform; because this is the most highly phosphorylated variant of IGFBP-1, this species would be expected to have the greatest retention time. To support this data, an aliquot of the IGFBP-1 purified from plasma by immunoaffinity chromatography also was analyzed by IEX HPLC (Fig. 3C) . A single peak of immunoreactivity, which coincided with peak e in the Hep G2 chromatogram, was observed when the fractions were analyzed with RIA 6303; however, as anticipated, RIA 6305 did not detect any IGFBP-1 in any of the fractions.
Characterization of IGFBP-1 isoforms in fractions from IEX-HPLC of HepG2 CM
To provide further evidence that IEX HPLC had separated the isoform corresponding to the plasma phosphoform from the other variants in the Hep G2-derived IGFBP-1, the fractions corresponding to the peaks were immunoprecipitated by MAb 6303 and analyzed by n-OG electrophoresis and Western ligand blotting (Fig. 4) . The phosphoform characteristic of NP was found in the fractions, coinciding with the immunoreactivity peak (peak e) detected by RIA 6303 but not RIA 6305. Figure 5 shows that the phosphoform purified from Hep G2 comigrates with the phosphoform purified from plasma and that both the Hep G2-derived and the plasma-derived IGFBP-1 are recognized by MAb 6303 but not by MAb 6305. To confirm that the Hep G2-and plasma-derived IGFBP-1 were phosphorylated, both isoforms were incubated with alkaline phosphatase for 2 h at 37 C. With the Hep G2-derived IGFBP-1, this resulted in the appearance of an isoform that comigrated with nonphosphorylated rhIGBP-1 and could be detected by MAb 6305 and MAb 6303. Although a 2-h incubation was insufficient for the complete dephosphorylation of the plasma-derived IGFBP-1, alkaline phosphatase did produce an isoform that comigrated with rhIGFBP-1 and was detected by MAb 6305.
Ligand-binding affinities of IGFBP-1 isoforms
To determine the effect of phosphorylation on IGFBP-1 binding of IGF, equilibrium binding studies were performed. Nonspecific binding constituted less than 25% of bound radiolabel in the absence of unlabeled IGF and less than 18% of the total amount of radiolabel added to each tube. Scatchard plots obtained for all isoforms of IGFBP-1 were linear, indicating the presence of a single binding site. Figure 6 shows the Scatchard analysis of IGF-I binding to rhIGFBP-1 and the phosphoform isolated from NP (before and after treatment with alkaline phosphatase). The mean (n ϭ 5) affinity constant of rhIGFBP-1 was 2.5 Ϯ 1.7 ϫ 10 9 m Ϫ1 (Table 1) , which is in accordance with previous reports (6). However, the affinity of the highly phosphorylated IGFBP-1 isolated from plasma was significantly greater at 2.3 Ϯ 1.1 ϫ 10 10 m Ϫ1 (n ϭ 5; P Ͻ 0.002), as was that of the highly phosphorylated isoform purified from HepG2 CM (P Ͻ 0.007; Table 1 ). There was no statistical difference between the affinity of the plasma-and Hep G2-derived phosphoforms for IGF-I, though the range in affinities determined for the latter isoform (1.3 ϫ 10 10 m Ϫ1 to 5.8 ϫ 10 11 m Ϫ1 ) resulted in a mean of 1.6 Ϯ 2.8 ϫ 10 11 m
IGF-I.
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. Dephosphorylation of the phosphorylated IGFBP-1 from plasma with alkaline phosphatase, though incomplete, resulted in a significant decrease in the affinity for IGF-I (2.3 Ϯ 1.1 ϫ 10 10 m Ϫ1 to 5.4 Ϯ 1.1 ϫ 10 9 m
; P Ͻ 0.004). 
IGF-II.
The Scatchard analysis of IGF-II binding to rhIGFBP-1 and the highly-phosphorylated IGFBP-1 purified from plasma is shown in Fig. 7 . The mean (n ϭ 5) affinity constant of rhIGFBP-1 for IGF-II was 1.8 Ϯ 3.0 ϫ 10 9 m Ϫ1 , which was not significantly different from the affinity constant for IGF-I ( Table 1 ). The affinity constant of the highly phosphorylated isoform derived from plasma and Hep G2 medium (3.6 Ϯ 2.0 ϫ 10 9 m Ϫ1 and 5.7 Ϯ 6.3 ϫ 10 9 m Ϫ1 , respectively) was no different from that of rhIGFBP-1. Hence, phosphorylation does not seem to affect the affinity of circulating IGFBP-1 for IGF-II. Therefore, the circulating phosphoform has a significantly higher affinity (P Ͻ 0.02) for IGF-I than for IGF-II (Table 1) .
Ligand-binding affinity of rhIGFBP-3
The affinity of rh (nonglycosylated) IGFBP-3 for IGF-I and -II was in accordance with previous reports (11, 12) . IGFBP-3 had a slightly higher affinity for IGF-II than IGF-I (1.8 Ϯ 2.3 ϫ 10 10 m Ϫ1 vs. 5.6 Ϯ 4.2 ϫ 10 9 m Ϫ1 ; Table 1 ), though this was not significant. However, there was a significant difference between the affinity of IGFBP-3 and the circulating isoform of IGFBP-1 for IGF-I; IGFBP-1 had a 4-fold higher affinity (P Ͻ 0.005) than IGFBP-3, the main IGF carrier in the circulation, though for IGF-II, the affinity of IGFBP-3 was no different from that of the highly phosphorylated isoform of IGFBP-1.
Discussion
We have reported that, in the normal circulation, IGFBP-1 is present as a single highly phosphorylated species. In this study, we have purified this previously uncharacterized isoform of IGFBP-1 to determine its ligand-binding affinity and the functional significance of IGFBP-1 phosphorylation. Circulating IGFBP-1 is produced by the liver, and therefore, human liver carcinoma (HepG2) cells also were investigated as a source of the plasma phosphoform of IGFBP-1. The plasma form of IGFBP-1 is produced by Hep G2 cells; however, unlike the liver, these cells also produce non-and lesserphosphorylated variants. This may be a result of altered intracellular kinase pathways or extracellular dephosphorylation of the highly phosphorylated isoform. Nevertheless, by using a combination of immunoaffinity chromatography and IEX HPLC, we were able to purify the individual IGFBP-1 isoforms to homogeneity for use in ligand-binding assays. The most highly phosphorylated IGFBP-1 isoform, produced by Hep G2 cells coeluted from IEX HPLC with plasma IGFBP-1, had identical mobility in the n-OG electrophoresis system and had a similar affinity for both IGF-I and IGF-II as plasma-derived IGFBP-1. Therefore, we conclude that Hep G2 cells provide an alternative and more accessible source of the circulating isoform of IGFBP-1.
The affinity of the plasma phosphoform for IGF-I was much greater than that reported for the phosphoforms present in AF (6) and was approximately 10-fold greater than nonphosphorylated IGFBP-1 seen in maternal plasma during pregnancy (12) ; thus, phosphorylation does increase the affinity for IGF-I, as anticipated from other studies (6) . Dephosphorylation of IGFBP-1 during pregnancy may result in IGF peptides, particularly IGF-I, being liberated from or more weakly bound to this altered circulating IGFBP-1, leading to increased IGF bioavailability for placental and fetal growth.
The affinity of the highly phosphorylated form of IGFBP-1 for IGF-I was also significantly higher than the affinity of IGFBP-3, the main carrier of IGF in the circulation. It is thought that the 150-kDa complex of IGFBP-3, IGF-I, or -II and the acid-labile glycoprotein (13, 14) is saturated with IGFs and serves as their endocrine storage site. In this form, the half-life of the IGF peptides is increased (16) ; 32). Enhancement of IGF action has been observed with IGFBP-1, -3, and -5. It is thought that this is facilitated by posttranslational modifications of the IGFBPs leading to altered IGF affinities. Association of IGFBP-3 with the cell surface (33) and binding of IGFBP-5 to the extracellular matrix (34) significantly lowers their affinities for IGFs, as compared with the soluble forms of these IGFBPs, therefore favoring IGF/receptor interactions. Similarly, proteolytic cleavage of IGFBP-3 (35, 36) and IGFBP-5 (37) lowers IGF affinities. IGFBP-2 (38) and -4 (39) also are susceptible, though the exact roles of these proteases in controlling the distribution of the IGFs in serum has not been determined. To date, no such protease has been described for IGFBP-1; we and others (12, 31) have suggested that changes in phosphorylation status may represent the mechanism by which IGFs are released by IGFBP-1. This hypothesis is supported by our finding that the normal circulating form of IGFBP-1 has a 10-fold higher affinity for IGF-I than the nonphosphorylated IGFBP-1 that appears during pregnancy. Whether change in IGFBP-1 phosphorylation status (for example, at the cell surface of IGF target tissues) represents a more generalized mechanism for controlling tissue IGF bioavailability remains to be determined, the analogy being that tissue IGFBP-3 proteolytic activity is reported to be 8-fold higher than in serum (40) .
All IGFBPs bind both IGF-I and -II with high specific affinity, and Rechler (30) has suggested that the affinity constants of the six IGFBPs are similar for IGF-I and IGF-II, with the exception of IGFBP-6, which has a 20-to 70-fold higher affinity for IGF-II, and that variations of some affinity constants found in the literature may be caused by different temperatures at which K a values were determined. In the present study, the binding affinity of the plasma form of IGFBP-1 for IGF-I and IGF-II was determined under the same conditions, and phosphorylation was found to affect only the affinity of IGFBP-1 for IGF-I. Although the explanation for this phenomenon is not clear, it may involve different binding sites for IGF-I and -II on IGFBP-1, as has been suggested recently for IGFBP-2 (41). These findings may also explain why Kratz et al. (42) were able to show enhanced proliferative response to IGF-I, but not IGF-II, in the presence of nonphosphorylated (recombinant) IGFBP-1 in human keratinocytes and fibroblasts. Scatchard plots obtained by Roghani et al. (43) also imply two classes of binding site for IGF-I and IGF-II, one of high and one of low affinity, though this is likely to be because their IGFBP-1 preparation was purified from AF and would have contained several different isoforms of IGFBP-1. Our Scatchard data gives linear plots, which would suggest that, when using a homogenous preparation of IGFBP-1, the binding of IGF-I or -II is at a single site.
In summary, we have purified the highly phosphorylated form of IGFBP-1 found in the normal circulation and have shown that this species has a significantly higher affinity for IGF-I in comparison with the nonphosphorylated isoform that appears under some physiological and pathological conditions. These data suggest that normally, IGFBP-1 in the circulation would be inhibitory of IGF actions; however, changes in IGFBP-1 phosphorylation status may permit increased IGF, particularly IGF-I, bioavailability.
